Product
Triple Intrathecal Chemotherapy
1 clinical trial
6 indications
Indication
Acute Myeloid LeukemiaIndication
Down syndromeIndication
Myelodysplastic SyndromeIndication
Recurrent Acute Myeloid LeukemiaIndication
Recurrent Mixed Phenotype Acute LeukemiaIndication
Mixed Phenotype Acute LeukemiaClinical trial
A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-Selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse TherapyStatus: Recruiting, Estimated PCD: 2024-12-31